Blepharophimosis, ptosis, epicanthus-inversus syndrome (BPES) is an autosomal dominant genetic disorder characterized by narrow palpebral fissures and eyelid levator muscle defects. BPES is often associated to premature ovarian insufficiency (BPES type I). FOXL2, a member of the forkhead transcription factor family, is the only gene known to be mutated in BPES. Foxl2 is essential for maintenance of ovarian identity, but the developmental origin of the facial malformations of BPES remains, so far, unexplained. In this study, we provide the first detailed account of the developmental processes leading to the craniofacial malformations associated to Foxl2. We show that, during development, Foxl2 is expressed both by Cranial Neural Crest Cells (CNCCs) and by Cranial Mesodermal Cells (CMCs), which give rise to skeletal (CNCCs and CMCs) and muscular (CMCs) components of the head. Using mice in which Foxl2 is selectively inactivated in either CNCCs or CMCs, we reveal that expression of Foxl2 in CNCCs is essential for the development of extraocular muscles. Indeed, inactivation of Foxl2 in CMCs has only minor effects on muscle development, whereas its inactivation in CNCCs provokes a severe hypoplasia of the levator palpabrae superioris and of the superior and inferior oblique muscles. We further show that Foxl2 deletion in either CNCCs or CMCs prevents eyelid closure and induces subtle skeletal developmental defects. Our results provide new insights in the complex developmental origin of human BPES and could help to understand the origin of other ocular anomalies associated to this syndrome.
due to a dysplasia, or absence, of the major eyelid elevator muscle: the levator palpebrae superioris (LPS) (2, 3) . Other ocular anomalies such as, refractive error, strabismus and amblyopia (4) are often associated to BPES. BPES diagnostic is mostly based on clinical examination of the patients. In female BPES patients, facial malformations can be associated (BPES type I) or not (BPES type II) to premature ovarian failure (5) . At least 88% of BPES type I and II patients present a mutation or a deletion of FOXL2 coding or regulatory sequences (OMIM 605597) (6) (7) (8) (9) (10) . The variability of BPES phenotype results from the diversity of the genetic lesion at the origin of the disease: FOXL2 mutations, modifications in shared regulatory sequences that can also affect the expression neighbouring genes or, in rare cases, chromosomic translocations (4) . Rarely, nystagmus, euryblepharon, ectropion, microphthalmos, microcornea, trabecular dysgenesis, optic nerve hypoplasias, colobomas of the optic disk and congenital alacrima have also been reported in putative BPES patients, often without a proven molecular diagnosis (4, (11) (12) (13) (14) (15) . FOXL2 codes for a forkhead/HNF3 transcription factor expressed in the developing and adult ovary (16, 17) . During mouse development, Foxl2 is also expressed by the periocular mesenchyme and in the mesodermal core of pharyngeal arches 1-3 (6, 18, 19) .
Craniofacial development requires long-distance migration, synchronized differentiation and cooperation of many cell types, including cranial neural crest cells (CNCCs) and cranial mesodermal cells (CMCs). CNCCs give rise to most chondrocranial and dermatocranial elements (20) (21) (22) . Conversely, CMCs are at the origin of craniofacial muscles and some posterior skeletal elements of the skull (22) (23) (24) (25) . Although the craniofacial expression of Foxl2 has been reported (6, 16) , the aetiology of BPES facial signs remains unexplained. It has been proposed that Foxl2 is predominantly expressed by CNCCs (26) , while some of the signs of the disease imply CMCs derivatives such as palpebral muscles.
Several murine models with mutations or invalidation of Foxl2 have been generated to study the specification and maintenance of ovarian identity, sex determination and fertility (18, 19, 27, 28) . Even if BPES in humans is caused by haploinsufficiency of FOXL2, many aspects of the human syndrome are well reproduced by mouse models carrying homozygous Foxl2 mutations. Although Foxl2 mutant mice present eyelid defects at birth with subsequent degeneration of the eye cups (6, 29, 30) , the developmental processes associating Foxl2 mutations to craniofacial development have been poorly analysed.
Here, we provide the first account of the aetiology of the craniofacial malformations associated to Foxl2 mutations. To this end, beside mice carrying a constitutive, global Foxl2 inactivation, we generated animals in which Foxl2 is selectively deleted either in CNCCs or in CMCs. Our analyses demonstrate for the first time the complex aetiology of the facial development, which implies both CNCCs and CMCs derivative providing a conceptual framework to decode the origin of human BPES facial defects.
Results

Foxl2 is expressed by CNCCs and CMCs derivatives
To determine the Foxl2 expression pattern during craniofacial development, we used a Foxl2
LacZ/+ strain (19) . At E8.5, during lens placode formation, Foxl2 is expressed in a restricted anterior region of the embryo at the level of the mesencephalon immediately caudal to the developing eye (Fig. 1A , E8.5); this region provides the CNCCs and CMCs (31, 32) that, at later developmental stages, participate to form periocular structures. At E9.5, β-Galactosidase (β-GAL) positive mesenchymal cells surround the eye, with the exception of its rostral aspect (Fig. 1A, E9 .5). Sections of E9.5 embryos show that, at the mesencephalic level, all mesenchymal cells, including migrating CNCCs and CMCs, as well as populations of non-neural ectodermal cells and endodermal cells are β-GAL positive while the neural ectoderm and post-migratory CNCCs in the first pharyngeal arch are negative (data not shown). As the eye develops, the periocular Foxl2 expression profile is maintained; eventually β-GAL positive cells completely surround the eye (Fig. 1A E10 .5-E13.5). Other structures expressing Foxl2 during craniofacial development include the maxillary arch, the pharyngeal endoderm, the mesodermal core of pharyngeal arches 1 and 2 (PA1, PA2) and their derivatives (Fig. 1A) . We used double immunohistochemistry to determine the identity of Foxl2-positive cells. At E11.5, a subpopulation of MYOD-positive periocular muscle precursors also expressed Foxl2 (Fig. 1B and B′ arrows) . We used Wnt1
ERT2Cre/+ ROSA LacZ/+ , a tamoxifen inducible Cre expressing mouse strain, which CNCCs progeny are permanently labelled by LacZ expression, to examine Foxl2 expression by CNCCs. When the effects of tamoxifen injection at E7 and E7.5 were analysed at E13.5, the majority of CNCCs derivatives in the lower eyelid were Foxl2-positive ( Fig. 1C and C′, arrowheads). We wondered which structures and cell types of the newborn mouse head derive from Foxl2 expressing cells. To this end, we analysed pups issued from a Foxl2
Cre/+ ROSA LacZ/+ crossing, permanently labelling Foxl2 expressing cells and their derivatives by LacZ expression. In the cephalic region of these mice, both CMCs and CNCCs derivatives were β-GAL positive including: (i) all the muscles derived from the mesodermal core of PA1 and PA2; ( 
Foxl2 is required for foetal eyelid closure
The eyelids of Foxl2-null mice (Foxl2-KO) are open at birth (6, 29, 30) ; the origin of this malformation has not been analysed.
To address this question, we monitored Foxl2 expression at key stages of ocular development and the consequences of its invalidation on palpebral formation. In mouse, eyelid protuberances appear at E13.5 and primitive eyelids are clearly visible at E15.5 ( Fig. 2B1 and B2 ). At E15.5, rounded peridermal cells at the eyelid margin proliferate and converge until complete eyelid closure at E16.5 ( Fig. 2B2 and B3, Supplementary Material, Fig. S2A ) (33) . Foxl2 is expressed by mesenchymal cells of the upper and lower eyelid precursors at E11.5 and E13.5, before overt eyelid formation ( Fig. 1B and C) . At E15.5, FOXL2 protein is present in most upper (Fig. 2A2) and lower ( Fig. 2A3 ) eyelid mesenchymal cells, in the extraocular muscles (Fig. 2A4) , in the frontal bone (Fig. 2A4 ) and in the Harderian gland (Fig. 2A5 ), but is absent from the eyelid epithelium (Fig. 2A1-A3 ) and other eye components.
In E13.5 Foxl2-KO embryos, eyelid protuberances are not yet visible (Fig. 2C1) . At E15.5, the periderm extension, which permits eyelid closure (33), does not form in Foxl2-KO (Supplementary Material , Fig. S2B ); in mutant foetuses, the defect of eyelid growth persists from E15.5 to P0 (Fig. 2C2-C4) resulting in an open eye phenotype at birth. Moreover, the Harderian gland is not present in Foxl2-KO mice (Fig. 2C3-C4 , black asterisks).
At E13.5 and E15.5, other eye components, including the neural retina, the lens and the cornea, develop normally in Foxl2-KO foetuses. From E16.5 to P0, in the absence of Foxl2, the eye becomes gradually more affected. In particularly, the cornea becomes thinner in mutant mice compared with controls ( Fig. 2B2-C4 , Supplementary Material, Fig. S2C-H) . At birth, the eye of Foxl2 mutants is abnormal, with a lens apposed to a thin cornea (Fig. 2C4) , an affected retinal pigment epithelium, and malformed choroid and scleral layers (Supplementary Material, Fig. S2G-J) .
Inactivation of Foxl2 interferes with the development of extraocular muscles
Extraocular muscles include the six oculomotor muscles that control eye movement (Superior, Inferior, Lateral and Medial rectus; Superior and Inferior oblique) and the muscles that control superior eyelid elevation: the levator palpebrae superioris (LPS) and the Müller's muscle (or superior tarsal muscle) (34), a small smooth muscle anchored to the LPS; eyelid closure is controlled by the orbicularis oculi muscle.
Human BPES is characterized by a dysplasia of the LPS leading to ptosis. Other ocular anomalies, such as strabismus and amblyopia, are often associated to BPES (4), suggesting possible defects of oculomotor muscles. To investigate the effect of Foxl2 inactivation on extraocular muscle development, we identified striated and smooth muscles by immunostaining for DESMIN and Smooth Muscle Actin (αSMA) on sections from Foxl2-KO and control foetuses. At E13.5, oculomotor muscles, including the superior and inferior rectus and the superior oblique, are already present in control foetuses (Supplementary Material, Fig. S3A-F) ; From E15.5 to P0, the oculomotor muscles, including the superior and inferior rectus, the retractor bulbi and the superior oblique, are present in Foxl2-KO foetuses, but with abnormal morphologies, anchorage points and trajectories compared with controls ( Fig. 3A-F) , as better analysed by 3D reconstructions at P0 (Fig. 4) . The abnormal eyelid development that we described in Foxl2-KO mice (Fig. 2) is accompanied by muscular defects. During normal development, a dramatic change occurs between extending periderm ( pe) (A2-A3). Foxl2 expressing cells are also observed in the frontal bone (fr) and in the oculomotor muscles such as the superior oblique (so) (A4). Moreover, Foxl2 expression is detected in the harderian gland (A5). (B1-C4) Haematoxylin and eosin staining of frontal sections in the periocular region of control (B1-B4) and Foxl2-KO (C1-C4) foetuses from E13.5 to P0. At E13.5, the protruding eyelids are less developed in Foxl2-KO mice whereas the eye does not show differences compared with controls. Later, Foxl2-KO foetuses present a defect of eyelid outgrowth resulting in an open-eye phenotype at birth (black arrowheads, C2-C4). The eyelid closure anomaly in Foxl2 mutants is associated to a thinning of the cornea. Note the absence of the harderian gland in the mutants (black asterisk C3-C4). c, cornea; ep, epithelium; fr, frontal bone; hg, harderian gland; le, lens; lel, lower eyelid; nr, neural retina; pe, peridermal cells; uel, upper eyelid; sc, sclera; so, superior oblique. http://hmg.oxfordjournals.org/ E15.5 and E16.5 in the size and shape of the orbicularis oculi ( Fig. 3A′-C′) , which parallels eyelid extension and forms the definitive eyelid muscle at P0 (Fig. 3E′ ). In contrast, in Foxl2-KO mice, the orbicularis persists as a hypoplastic muscular mass at the base of the undeveloped eyelid, and does not extend as in control animals (Fig. 3B′ , D′ and F′). In addition, in normal animals, the LPS reaches the eyelid from E16.5 to P0. The LPS acts as the major eyelid opening muscle, while a second levator muscle, the Müller smooth muscle, binds to the superior tarsus, an elongated plate of connective tissue at the eyelid margin (Fig. 3E′ ). In mutants, we observed neither the LPS nor the Müller muscle at the level of the hypoplastic eyelid (Fig. 3F′) . As an additional defect, Foxl2-KO foetuses lack a differentiated frontal muscle at all stages analysed (Fig. 3B , B′, D and F, white asterisks).
We conclude that extraocular muscle malformations in Foxl2-KO mice begin early during craniofacial morphogenesis and that the most severely affected muscles are those involved in eyelid opening (LPS, Müller) and closure (orbicularis oculi).
Foxl2 invalidation in CNCCs recapitulates extraocular muscle defects of Foxl2-null mice
Given the complex spatial organization of the muscles in the eye region, we performed 3D segmentation of bones, cartilages and muscles in the periocular region of newborn mice, as shown in Figure 4A1 -A1″. As Foxl2 is expressed both in CNCCs and in CMCs (Fig. 1) , we wondered whether the origin of the defect was to be found in either of these populations or in both. To this end, we compared the periocular morphology of control newborn mice ( From E15.5 to P0, DESMIN is present in the differentiated oculomotor muscles, including the superior and inferior rectus (sr and ir), the retractor bulbi (rb) and the superior oblique (so) (A, C, E). Foxl2 mutants present morphological differences of oculomotor muscles (B, D, F) and an insertion defect of the superior oblique (B-D and B′-D′). From E15.5 to E16.5 in control foetuses at the eyelid level, the orbicularis oculi (oo) precursor follows the eyelid outgrowth to form the final muscle at P0. In parallel, the levator palpebrae superioris (lps) develops from E16.5 to P0 in the eyelid (C′-E′) and the Müller muscle (mu) differentiates in the palpebral structure (E′). In Foxl2-KO foetuses, the defect of eyelid formation (B′, D′, F′ white arrowheads) leads to the presence of a muscle mass which corresponds to the not elongated orbicularis oculi (B, D, F, B′, D′, F′). Foxl2 inactivation also provokes the absence of differentiated lps and Müller muscles in the hypoplastic eyelid (green asterisks D′, F′). Note that the frontal muscle does not develop in Foxl2 mutants (B, B′, D white asterisks). c, cornea; ir, inferior rectus; lel, lower eyelid; lps, levator palpebrae superioris; mu, Müller muscle; oo, orbicularis oculi; rb, retractor bulbi; so, superior oblique; sr, superior rectus; uel, upper eyelid. Scale bars in A-F 250 µm and in F′ for A′-F′100 µm.
CNCCs results in similar eyelid phenotypes that observed in mice constitutively deleted for Foxl2 (Supplementary Material, Fig. S4 ).
We first analysed the morphology of the LPS, of particular interest for a BPES murine model. In Foxl2-KO mice, the LPS is present, but does not reach the upper eyelid as in controls and impairs LPS extension to the eyelid. (A3-D3) In all cases, four rectus muscles develop around the eye, despite different sclera (grey) morphologies. (A4-D4) In control animals (A4) the superior oblique muscle follows a complex trajectory reaching first the trochlear region (t) and then sharply changing of direction and contacts the superior part of the sclera. In Foxl2-KO mice, the superior oblique does not exit the trochlear region (B4). In Foxl2-KO mesoderm mice (C4) the superior oblique follows a normal trajectory, although its contact zone with the sclera appears more focal. Whereas in Foxl2-KO cncc (D4), the superior oblique is hypomorphic and fails to reach the sclera. (A5-D5) The inferior oblique muscle is present in control (A5) and Foxl2-KO mesoderm (C5), but is absent in Foxl2-KO and Foxl2-KO cncc mice (B5 and D5). Scale bars in A1 for A1-D1 and in A2 for A2-D5 1 mm.
Human
at Walaeus Library LUMC on February 9, 2016 http://hmg.oxfordjournals.org/ attaches, instead, to the frontal bone (Fig. 4A2-B2 ). Foxl2-KO cncc mice recapitulate the LPS phenotype of Foxl2-KO mice (Fig. 4D2 ). In contrast, in Foxl2-KO mesoderm mice, the LPS retained its natural attachment point on the hypoplastic eyelids, but the lateral extension of the muscle was reduced (Fig. 4C2 ) compared with controls (Fig. 4A2) .
In each genotype, the four branches of the rectus muscle were present (Fig. 4A3-D3 ) and well positioned around the sclera, however, in Foxl2-KO mice, the rectus muscles apparently covered a larger portion of the sclera surface.
The two oblique muscles, superior and inferior, were severely affected in Foxl2-KO mice. In control animals, the superior oblique muscle first reaches the trochlea and then turns sharply towards the sclera (Fig. 4A4) . In Foxl2-KOs, only a small proximal segment of the superior oblique muscle persists, it is anchored to the frontal bone and does not reach the sclera (Fig. 4B4) ; the invalidation of Foxl2 in CNCCs results in a similar phenotype (Fig. 4D4) . Foxl2 invalidation in CMCs results in a more subtle phenotype: the superior oblique connects the orbit to the sclera passing through the trochlea, although its anchorage to the sclera is more focal (Fig. 4C4) . The inferior oblique is absent both in Foxl2-KO and in Foxl2-KO cncc ( Fig. 4B5 and D5 ), and has a normal morphology in Foxl2-KO mesoderm mice ( Fig. 4A5 and C5 ).
The ocular muscle defects observed in the Foxl2 mutants are summarized in Table 1 .
Skull-bone defects in Foxl2 mutant mice
Since Foxl2 is expressed by CNCCs and CMCs (Fig. 1) , which both give rise to craniofacial skeletal components (22), we analysed the bone phenotype of globally Foxl2-invalidated newborn mice. At birth, Foxl2-KO mice present ossification defects of the neurocranium components including the frontal, squamosal, parietal and interparietal bones (Fig. 5A1-B1 ). The analysis of the cranial base reveals that the lesser wings of the presphenoid are dramatically reduced compared with controls, while the basisphenoid and basioccipital bones are not affected (Fig. 5A2-A3 and B2-B3). Foxl2-KO mice also show a fusion of the maxillary bone with the premaxillary and jugal components (Fig. 5A4-A5 and B4-B5). In the reporter Foxl2
Cre/+ ROSA LacZ/+ line at P0, the lesser wings of the presphenoid, the premaxillary, the maxillary and the jugal bones express LacZ (Supplementary Material, Fig. S1C -E) strongly suggesting the implication of Foxl2 in the formation of the latter structures. In Foxl2-KO mesoderm mice, defects of the parietal and interparietal bones and of the lesser wing of the presphenoid bone (CMCs-derived) are similar to that observed in Foxl2-KO mutants, the frontal bone and the maxillary components are not affected (CNCC derived) (Fig. 5C ). In contrast, Foxl2-KO cncc mice show a fusion of the maxillary, premaxillary and jugal bones (CNCCs-derived) associated to a normal presphenoid phenotype (Fig. 5D) . The craniofacial bone defects observed in the Foxl2 mutants are summarized in Table 1 .
Discussion
The developmental origin underlying BPES facial malformations in humans has not been elucidated so far. Here, taking advantage of several mouse models of invalidation of Foxl2, we address the question of the Foxl2 involvement in craniofacial development. We show that Foxl2 is expressed by both CNCCs and CMCs, and is required for correct periocular muscle and bone morphogenesis. Using selective inactivation of Foxl2 in CNCCs or in CMCs, we are able for the first time to demonstrate that, although both populations are important, CNCCs provide the topological cues needed for the morphogenesis of certain CMCsderived extraocular muscles such as the LPS or the oblique muscles.
Foxl2 expression during craniofacial development
Although Foxl2 expression during development of the mouse cephalic region has been reported (6, 18, 19, 35) , our results provide the first precise account of its spatio-temporal expression during craniofacial development. At E8.5/E9.5, Foxl2 is expressed by most cells present in a restricted region of the head at the level of the mesencephalon including migratory CNCCs and CMCs. This restricted pattern of expression suggests that FOXL2 participates in the complex regulatory networks which define specific craniofacial regions, and that genetic mechanisms must exist to limit its expression anteriorly and posteriorly. At later stages, Foxl2 expression is maintained in the mesodermal core of the first pharyngeal arch and in CNCCs of the maxillary arch, but is down regulated in CNCCs of the mandibular arch (Fig. 1A) possibly through a Dlx5/6-dependent mechanism (18, 35) . In the periocular region, Foxl2 expression persists until eyelid fusion (E16.5); afterwards its level of expression in the eyelids diminishes to be hardly detectable at birth (30) (data not shown). The data suggest that Foxl2 has a central role in early eyelid development and eyelid extension. As eyelids are structures specific to gnathostomes (36), Foxl2 might have been essential for their appearance during vertebrate evolution. Interestingly, Foxl2 expression has been reported during foetal eyelid development of the dogfish and the goat (16, 37) , suggesting a conserved and ancestral role in eyelid development. The comparative analysis of Foxl2 sequences in different species reveals that the Foxl2 coding region is highly conserved in vertebrates (16, 38) . The analysis of Foxl2 expression in the cephalic region of other species such as lampreys, amphioxus and hagfish might shed light on the evolutionary origin of eyelids in vertebrates.
Role of Foxl2 in eye and eyelid development
We show that, at the ocular level, Foxl2-positive precursors contribute to form the sclera delimitating the corneal structure, the suspensory ligaments in contact to the ciliary body, the retinal pigment epithelium and the choroid coat apposed to the neural retina (Supplementary Material, Fig. S1F-H) . In contrast Foxl2 Fig. S2I and J) , suggesting a direct role of Foxl2 in the development of these structures. During early development, the cornea of Foxl2-KO mice is normal. At later stages, however, the cornea is much thinner and the whole eye morphology is affected (Fig. 2, Supplementary Material,  Fig. S2C-H) . Some data suggest that defects of eyelid closure might be at the origin of corneal anomalies (39, 40) ; a closed eyelid is required for the development of ocular surface (40) . The corneal degeneration observed in the Foxl2-KO newborns might be secondary to the failure of eyelid closure.
Our results reveal that Foxl2-positive precursors contribute to form periocular bones and muscles (Fig. 1D , Supplementary Material, Fig. S1B-E) , and all structures constituting the core of the upper and lower eyelids, but not to the overlaying eyelid epidermis (Fig. 1D, Fig. 2A2-A3 and Supplementary Material, Fig. S1B and F) . The data suggest an abnormal mesenchyme-epithelial interaction preventing peridermal extension during eyelid closure ( Fig. 2 and Supplementary Material, Figs S2 and S4) . The upper and lower eyelids have different embryonic origin (CMCs and CNCCs, respectively) (41) and invalidation of Foxl2 in either CMCs, CNCCs or both results in similar eyelid phenotypes in which eyelids are hypoplastic (Supplementary Material, Fig. S4 ). These findings suggest that the expression of Foxl2 results in common developmental effects in cell populations of different origin.
Role of Foxl2 in extraocular muscles development
In Foxl2-KO mice, the LPS and the SO muscles are present, but are severely affected: they do not present their natural points of attachment on the superior eyelid and on the sclera but display, instead, abnormal attachment points on the frontal bone ( Figs 3D, F  and 4B ). This phenotype is reminiscent of human BPES in which the LPS is either absent or hypoplastic (2, 3) . Remarkably, although the LPS and the SO muscles derive from the mesoderm, these muscle present abnormal attachment points when Foxl2 is invalidated only in CNCCs, but have normal connections when Foxl2 is inactivated in CMCs (Fig. 4C and D, Table 1 ). In Foxl2-KO mesoderm mice, ocular muscles such as the rectus, the LPS and the SO appear, however, reduced in size. In Foxl2-KO, the SO develops enough to contact at E15.5 its distal target, the sclera (Fig. 3B , B′ and Supplementary Material, Fig. S2 ), although its trajectory is aberrant since the characteristical shape of this with the premaxillary ( pmx) (A4-B4, white arrow and asterisk) and jugal ( jg) components (A5-B5, black arrow and asterisk). In Foxl2-KO mesoderm mice, neurocranium and presphenoid bone defects are similar to those observed in Foxl2-KO mutants (C1-C3), whereas the maxillary components are not affected (C4-C5). In contrast,
Foxl2-KO cncc mice show a fusion of the maxillary, premaxillary and jugal bones associated to a normal presphenoid phenotype (D3-D5). Scale bars shown in D2 for A1-D2 1 mm and in D5 for A3-D5 500 µm.
at Walaeus Library LUMC on February 9, 2016 http://hmg.oxfordjournals.org/ muscle, through the CNCCs-derived trochlea, is absent (Fig. 3A,A′ and B,B′, Supplementary Material, Fig. S2 ). It is only in a second time, at E16.5, the eyelid closing stage, that the superior oblique looses its scleral attachment and binds to the frontal bone ( Fig. 3D and D′) , where it remains attached until birth (Figs 3E,F and 4). This indicates that the superior oblique does not require Foxl2 for initial growth and extension. In Foxl2-KO mice, the LPS never extends to the upper eyelid, but is attached to the frontal bone ( Figs 3D,D' and 4B2) . Since muscle-target recognition requires compatible adhesion cues (42) , the absence of Foxl2 in CNCCs could modify the identity of CNCCs-derivatives including tendons and bones leading to LPS and SO misrecognition of their targets.
Therefore, Foxl2 expression in the mesoderm could have a cell autonomous, trophic role in determining muscle size, while its expression in CNCCs could be required to determine the positioning of extraocular muscles. Consistently with our finding, previous studies also implicated CNCCs in the development of craniofacial muscles by regulating their patterning, proliferation and differentiation (43, 44) . The absence of FOXL2 might change CNCCs properties, thereby preventing normal muscular development. Furthermore CNCCs might play an important role in the scaffolding of muscle attachment points, as they are progenitors of tendons, cranial bones and cartilages.
The inferior oblique is absent in Foxl2-KO and Foxl2-KO cncc mice, suggesting that a CNCCs Foxl2-dependent signal is required for its development. Our findings suggest complex pleiotropic roles of Foxl2 in periocular muscle morphogenesis which could be differently modulated by the genetic background or by the type of Foxl2 mutation, resulting in a large spectrum of phenotypes as observed BPES patients.
Role of Foxl2 in skeletal development
Here we have shown that, beside muscular defects, inactivation of Foxl2 induces also subtle craniofacial skeletal defects. For example, the jugal-maxillary and the maxillary-premaxillary junctions are absent in Foxl2-KO mice, resulting in the fusion of these bones ( Fig. 5B4 and B5) ; these bones are CNCCs derivatives and, as expected, this phenotype is observed in Foxl2-KO cncc mice ( Fig. 5D4 and D5). Recently, craniofacial skeletal alterations partially overlapping those described in this report, have also been reported in mice carrying a piggyBac insertion mutation upstream of Foxl2 resulting in a reduced, but not absent, expression of the gene (18) . The skeletal alterations observed in piggyBac insertional mutants 14 days after birth include a maxillary-premaxillary dysmorphology which could derive from an embryonic defect similar to what we observe after Foxl2 inactivation. The lesser wings of the sphenoid derive from CMCs, and attach to the body of the sphenoid, which is a CNCCs derivative (22) . Consistently with their embryonic origin, we observe the absence of the lesser wings of the sphenoid in Foxl2-KO mesoderm , but not in Foxl2-KO cncc mice (Fig. 5A3-D3 ).
As craniofacial bones are the targets for craniofacial muscle recognition, Foxl2 seems to be implied in a complex dialogue between structures to determine their mutual positioning.
Analysis of cranial morphology of BPES patients has shown a relatively normal phenotype (4), however, minor features include a broad nasal bridge, low-set ears and a short philtrum (45) .
Our phenotype has been analysed at birth, when, in the mouse, different skull bony elements are not yet fused. Although it might be difficult to compare our findings to those observed in BPES patients after bone fusion has taken place, our analysis might pave the way for a better understanding of human craniofacial signs of the disease.
BPES aetiology: lessons from Foxl2 conditional mouse mutants
Foxl2 mutant mice are good models of BPES ovarian phenotype (19, 29) ; conditional inactivation of the gene in adult ovary has shown its importance to prevent transdifferentiation of an adult ovary to a testis (28) . Although these mice present obvious craniofacial defects, no in-depth analysis of the origin of their facial phenotype has been reported. Here we show that Foxl2 mutants recapitulate most of the facial signs of BPES and are, therefore, a useful tool to understand the aetiology of the morphological defects associated to the disease in particular, and the complex interplay of mammalian facial development in general.
The LPS phenotype in BPES is still controversial. It has been reported that BPES patients show absence or hypoplasia of LPS (3). In contrast, two other studies demonstrated that the posterior part of the LPS is present in the orbital region while the anterior LPS aponeurosis is dramatically disorganized at the eyelid level (2, 46) . These last observations are consistent with what we observe in Foxl2 mutants. We show that the LPS is present in Foxl2 mutants; however, it never enters the superior eyelid and has, instead, an anchorage point on the frontal bone (Figs 3 and 4) .
Other ocular anomalies such as defects in optical acuity (associated with retina or lens defects, e.g. hyperopia or astigmatism), defects in oculomotor muscle functions (strabismus, nystagmus), defects in lower palpebral development and eyelid margin (euryblepharon, ectropion) and abnormal eye morphology (microphthalmos, microcornea, trabecular dysgenesis, optic disc coloboma) (4, (11) (12) (13) (14) (15) are present at lower penetrance in BPES patients without, however, a proven molecular diagnosis. Our findings could help to understand the origin of rare BPES-associated phenotypic defects and determine their possible association with FOXL2. For example, abnormal oculomotor muscles (oblique muscles) might explain strabismus and nystagmus; lower palpebral formation and eyelid marginal defects could be a direct consequence of abnormal eyelid development; defects in optical acuity and abnormal eye morphology might be associated to dysgenesis of the sclera, of the suspensory ligaments of the ciliary body or of the choroid and retina which are involved in coloboma pathologies.
We show that Foxl2 is expressed during craniofacial glandular development, including the lacrimal, salivary and harderian glands ( Fig. 2 and Supplementary Material, Fig. S4 ). In mouse, the harderian gland produces the tear lipids, which prevent tear evaporation. The harderian gland is absent in humans (47) , and tear lipids are produced by the meibomian glands. Interestingly, congenital lacrimal puncta anomalies and, more rarely, alacrima, associated or not to the absence of lacrimal glands are present in BPES patients (15, 48) . Foxl2 inactivation in the mouse leads to the CNCCs-dependent absence of harderian glands (Fig. 2) , while the lacrimal and the salivary glands are still present (data not shown) revealing a novel role of Foxl2 on craniofacial glandular development.
The BPES facial phenotype is characterized by a defect of eyelid formation. During human development, eyelid fusion is completed at 9 weeks post-fertilization with subsequent reopening at 20 weeks (49) . From 9 to 14 weeks, the orbicularis oculi, the LPS and the Müller muscles develop within the fused upper eyelids (49) . Our data suggest that several aspects of the BPES facial phenotype might derive from a problem in palpebral development during the eyelid closure/reopening process. It might, therefore, be interesting to analyse the eyelid closure/reopening process in human foetuses at risk of BPES through prenatal high-resolution ultrasound examination, which may permit detection of early abnormal eyelid development as early as 12-13 weeks.
Materials and Methods
Animals
Procedures involving animals were conducted in accordance with the directives of the European Community (council directive 86/609) and the French Agriculture Ministry (council directive 87-848, 19 October 1987, permissions 00782 to GL).
Foxl2 expression pattern was studied using a knockin Foxl2 Cre/lox and Foxl2 LacZ/LacZ mice. Mice were maintained on a mixed (Black6/CD1) background. Embryos up to E16.5 were fixed by overnight immersion in 4% paraformaldehyde at 4°C. Newborn mice were fixed by transcardiac perfusion with 4% paraformaldehyde and post-fixed for 2 h in the same fixative. After fixation, P0 mice heads were decalcified for 2 days with Jenkin's solution (4% hydrochloric acid 37%, 3% acetic acid, 10% chloroform, 10% dH 2 O, 73% absolute ethanol). Samples were either cryoprotected in 30% sucrose, frozen and 20 µm thick cryostat sectioned, or dehydrated, embedded in paraffin and 12 µm thick microtome sectioned.
Immunohistochemistry
Sections were incubated overnight at 4°C with the primary antibodies diluted in PBS 3% BSA 0.025% Triton (for anti-FOXL2) or in PBS 5% SVF (others) with the following dilutions: rabbit anti-DES-MIN (Abcam AB15200, 1:800), rabbit anti-FOXL2 (Thermo Scientic PA1-802, 1:400), mouse anti-SMA (Sigma-Aldrich A5228, 1:4000), chicken anti-β-GAL (AVES labs, 1:2000), rabbit anti-MYOD (Santa-Cruz C-20:sc-304, 1:1200).
Immunohistochemistry was performed using standard protocols of the Dako Envision kit and the Dako ARK kit for DAB staining. Fluorescent immunohistochemistry were performed using species-specific fluorescent secondary antibodies (Jackson ImmunoResearch; 1:500) that were incubated for 2 h at room temperature, and counterstained with Dapi (Sigma-Aldrich).
Skeletal preparation
P0 mice were placed in tap water O/N at 4°C, then in boiling water for 20-30 s in order to remove the skin and placed in ethanol 95% O/N. They were washed in distilled water and immersed in the Alcian blue for 24 h to stain the cartilaginous structures. Samples were washed in 70% ethanol for 6-8 h, transferred to a solution of 1% KOH for 5 min and placed overnight in Alizarin red to stain bony structures. They were thinned in a solution of 1% KOH/glycerol 20% for 2 days and stored in a solution of 1% KOH/ glycerol 2:8.
Histological staining and 3D segmentation
For histological staining, classical Haematoxylin and Eosin stainings were performed on E13.5 to P0 heads paraffin sections using stabilized haematoxylin and 1% aqueous eosin solutions (RAL diagnostics, France).
For 3D reconstruction, heads from P0 mice were fixed in Bouin's solution (Sigma, France), decalcified for 2 days with Jenkin's solution, paraffin embedded and sectioned as described. Complete sets of frontal sections were stained by Mallory's trichromic as in Everett and Miller (53) to reveal histological differences between tissues. Pictures from all the sections were aligned, piled and registered using the Fiji plug-in of NIH ImageJ 'Register Virtual Stack Slices' (http://fiji.sc/wiki/index.php/ Register_Virtual_Stack_Slices). The aligned pictures from these sections were analysed with Mimics (Materialise, Belgium), a 3D segmentation software.
β-Galactosidase detection
For whole-mount LacZ expression analysis, embryos were immersed in 5-bromo-4-chloro-3-indolyl-beta--galactopyranoside (X-GAL) at 30°C for 24 h. Newborn heads were stained in toto after skin removal. For X-GAL staining on sections, heads were cryoprotected in 1× PBS-30% sucrose, then sectioned at 50 µm with a cryostat. β-Galactosidase activity was then revealed by immersing the free-floating sections in X-GAL at 30°C for 24 h. These sections were counterstained with a 1% acqueous eosin solution (RAL diagnotics, France)
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